Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05250284 · ClinicalTrials.gov registry record
The Intersection of Oncology Care and Worker Well-Being
A clinical trial of Solid Tumor, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- 400
- Enrollment target
- 1
- Study location
NCT05250284: Recruiting study of Solid Tumor, sponsored by University of Colorado, Denver.
NCT05250284 is a study of Solid Tumor that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 400 participants, above the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target (82% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05250284, a study of Solid Tumor, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
The goals of this study will be a greater understanding of cancer patients' well-being experience through the care/treatment continuum. An important aspect of the study is an understanding of work- and treatment-related challenges experienced by low-income men, many of whom will be Latino. At the 12-month observation period, the investigators will learn whether these men work long-term and how work status relates to well-being.
Primary Outcome
Employment and weekly hours worked will be assessed using questions from the Current Population Survey (CPS)
Conditions Studied
Interventions
- BEHAVIORAL WellBQ
- BEHAVIORAL PROMIS
Study Locations (1)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2022-04-04 |
| Est. Completion | 2027-08 |
What NCT05250284 shows while recruiting
NCT05250284 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target (82% higher).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which WellBQ is the first listed.
NCT05250284 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT05250284 about?
NCT05250284 is a clinical study titled "The Intersection of Oncology Care and Worker Well-Being". The goals of this study will be a greater understanding of cancer patients' well-being experience through the care/treatment continuum. An important aspect of the study is an understanding of work- and treatment-related challenges experienced by low-income men, many of whom will be Latino. At the 12...
What is the current status of trial NCT05250284?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2022-04-04. Estimated completion is 2027-08.
What conditions does trial NCT05250284 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT05250284?
The interventions under investigation include: WellBQ (BEHAVIORAL), PROMIS (BEHAVIORAL).
Who is sponsoring clinical trial NCT05250284?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05250284 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05250284's enrollment target sits among peer trials
400 12th of 196 higher than 184 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
RECRUITING · Phase 3
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI